Mamitaro Ohtsuki - Concepedia

Author

Mamitaro Ohtsuki

Also Known As

Hironobu Ihn, Kebukawa, Yoko, M OHTSUKI, M Ohtsuki, M. Ohtsuki, MAMITARO OHTSUKI, Mamitaro OHTSUKI, Mamitaro OHtsuki, Mamitaro Ohtsuki, Mamitaro, Ohtsuki

341

Publications

9.4K

Citations

H-Index

116

Concepts

All Affiliations

Jichi Medical University Jikei University School of Medicine Nagoya City University NTT Medical Center Fukuoka University

About

Mamitaro Ohtsuki is an author at Jichi Medical University specializing in medicine, dermatology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	45	2.4K
2	Allergy	6	6	189
3	Natural Sciences	2	2	92
4	Health Sciences	1	1	29
5	Public Health	1	1	16

Mamitaro Ohtsuki

107

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, New England Journal of Medicine	2016	818
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, The Lancet Autoimmune DiseaseMedicineClinical TrialsClinical DermatologyModerate-to-severe Plaque Psoriasis	2018	627
Guidelines for management of atopic dermatitis Hidehisa Saeki, Masutaka Furue, Fukumi Furukawa, The Journal of Dermatology	2009	264
Antitumor Activity of IFN-λ in Murine Tumor Models Atsuko Sato, Mamitaro Ohtsuki, Megumi Hata, The Journal of Immunology	2006	192
Epidermal growth factor and transforming growth factor alpha specifically induce the activation- and hyperproliferation-associated keratins 6 and 16. Chuan-Kui Jiang, Thierry Magnaldo, Mamitaro Ohtsuki, Proceedings of the National Academy of Sciences Epidermal Growth FactorHyperproliferation-associated Keratins 6Cell ProliferationDermatologyCell Growth	1993	189
Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52‐week analysis from phase <scp>III</scp> open‐label multicenter Japanese study Shinichi Imafuku, Masaru Honma, Yukari Okubo, The Journal of Dermatology	2016	186
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, The Journal of Dermatology	2010	181
Astaxanthin attenuates the UVA-induced up-regulation of matrix-metalloproteinase-1 and skin fibroblast elastase in human dermal fibroblasts Kaoru Suganuma, Hiroaki Nakajima, Mamitaro Ohtsuki, Journal of Dermatological Science Human Dermal FibroblastsCutaneous BiologyPathologySkin Fibroblast ElastaseWound Healing	2010	148
Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks Kristian Reich, Richard B. Warren, Lars Iversen, British Journal of Dermatology	2019	137
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce Strober, Craig L. Leonardi, Kim Papp, Journal of the American Academy of Dermatology	2016	130

Page 1